Drinking to death: Hyponatraemia induced by synthetic phenethylamines.
Ana Carolina Faria, Helena Carmo, Félix Carvalho, João Pedro Silva, Maria de Lourdes Bastos, Diana Dias Da Silva
Drug and Alcohol Dependence July 1, 2020 DOI: 10.1016/j.drugalcdep.2020.108045 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | 3,4-Methylenedioxymethamphetamine MDMA, Ecstasy Serotonin syndrome Synthetic cathinone |
| Key findings | Phenethylamines such as MDMA and synthetic cathinones can cause hyponatraemia through increased ADH secretion and water retention, with contributing factors of diaphoresis and polydipsia. Severe cases may lead to cerebral oedema, herniation, coma, and death, especially in women. The authors recommend controlled fluid intake, prompt medical care, and correction of severe hyponatraemia (<130 mmol/L) with hypertonic saline or fluid restriction. |
Abstract
Synthetic phenethylamines are widely abused drugs, comprising new psychoactive substances such as synthetic cathinones, but also well-known amphetamines such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Cathinones and amphetamines share many toxicodynamic mechanisms. One of their potentially life-threatening consequences, particularly of MDMA, is serotonin-mediated hyponatraemia. Herein, we review the state of the art on phenethylamine-induced hyponatremia; discuss the mechanisms involved; and present the preventive and therapeutic measures. Hyponatraemia mediated by phenethylamines results from increased secretion of antidiuretic hormone (ADH) and consequent kidney water reabsorption, additionally involving diaphoresis and polydipsia. Data for MDMA suggest that acute hyponatraemia elicited by cathinones may also be a consequence of metabolic activation. The literature often reveals hyponatraemia-associated complications such as cerebral oedema, cerebellar tonsillar herniation and coma that may evolve to a fatal outcome, particularly in women. Ready availability of fluids and the recommendation to drink copiously at the rave scene to counteract hyperthermia, often precipitate water intoxication. Users should be advised about the importance of controlling fluid intake while using phenethylamines. At early signs of adverse effects, medical assistance should be promptly sought. Severe hyponatraemia (<130 mmol sodium/L plasma) may be corrected with hypertonic saline or suppression of fluid intake. Also, clinicians should be made aware of the hyponatraemic potential of these drugs and encouraged to report future cases of toxicity to increase knowledge on this potentially lethal outcome.
Citations in the library
Cited by 5
- Pharmacologic Similarities and Differences Among Hallucinogens The Journal of Clinical Pharmacology August 1, 2021
- Use characteristics and harm potential of ecstasy in The Netherlands Drugs Education Prevention and Policy September 10, 2020
- Rare but relevant: MDMA and hyponatraemia Addiction December 8, 2025
- MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions Psychedelics October 14, 2025
- Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. Neurotoxicity Research December 2021
Cites 30
- The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences March 1, 1992
- Human Pharmacology of MDMA Therapeutic Drug Monitoring March 19, 2004
- Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacology March 3, 2006
- Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat Journal of Neuroscience July 1, 1998
- The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats British Journal of Pharmacology 2002
and 25 more in the library